Abbott Seeks to Terminate Alere Acquisition
By Sanjit Dutt Posted on 13 Dec 2016 |
Abbott Laboratories (Abbott Park, IL, USA) has filed a complaint in the Delaware Court of Chancery seeking termination of its proposed acquisition of Alere (Waltham, MA, USA), citing material adverse events after both the companies had entered into a merger agreement on January 30, 2016.
Over a period of 10 months since the merger agreement, Alere has witnessed some developments that have negatively impacted its business. These developments include the elimination of the billing privileges of a substantial Alere division by the government, permanent recall of a key product platform, a number of new government subpoenas, a five-month delay in its 10K filing, and admission of internal control failures requiring a restatement of the company’s 2013-2015 financials. As per the terms of the merger agreement, Abbott is entitled to terminate the transaction in case adverse events materially change Alere's long-term prospects.
"Alere is no longer the company Abbott agreed to buy 10 months ago," said Scott Stoffel, divisional vice president of external communications, Abbott. "These numerous negative developments are unprecedented and are not isolated incidents brought on by chance. We have attempted to secure details and information to assess these issues for months, and Alere has blocked every attempt. This damage to Alere's business can only be the result of a systemic failure of internal controls, which combined with the lack of transparency, led us to filing this complaint."
Related Links:
Abbott Laboratories
Alere
Over a period of 10 months since the merger agreement, Alere has witnessed some developments that have negatively impacted its business. These developments include the elimination of the billing privileges of a substantial Alere division by the government, permanent recall of a key product platform, a number of new government subpoenas, a five-month delay in its 10K filing, and admission of internal control failures requiring a restatement of the company’s 2013-2015 financials. As per the terms of the merger agreement, Abbott is entitled to terminate the transaction in case adverse events materially change Alere's long-term prospects.
"Alere is no longer the company Abbott agreed to buy 10 months ago," said Scott Stoffel, divisional vice president of external communications, Abbott. "These numerous negative developments are unprecedented and are not isolated incidents brought on by chance. We have attempted to secure details and information to assess these issues for months, and Alere has blocked every attempt. This damage to Alere's business can only be the result of a systemic failure of internal controls, which combined with the lack of transparency, led us to filing this complaint."
Related Links:
Abbott Laboratories
Alere
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus